Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theravance has reported positive results from a third lung function trial comparing the efficacy and safety of Anoro Ellipta (umeclidinium /vilanterol, UMEC/VI) with the LAMA tiotropium, administered in the HandiHaler inhaler, in patients with chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
Anoro Ellipta is a combination of long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA).
The 24-week, blinded, parallel group, multicenter trial evaluated the efficacy and safety of UMEC/VI 62.5/25mcg inhalation powder administered once-daily in the dry powder inhaler, Ellipta, compared to tiotropium 18mcg administered once-daily in the HandiHaler inhaler.
The trial enrolled a total of 905 patients with COPD and they were randomized 1:1 to UMEC/VI 62.5/25mcg inhalation powder or tiotropium 18mcg.
At the end of the treatment period, UMEC/VI 62.5/25mcg showed a statistically significant improvement of 112mL compared with tiotropium 18mcg.
The most commonly reported side effects for both UMEC/VI and tiotropium included headache, nasopharyngitis, cough and back pain.
Theravance president and chief executive officer Michael Aguiar said: "We believe the results from this positive study will provide physicians with additional useful data regarding the potential benefits of Anoro Ellipta as a treatment option for appropriate patients with COPD."